Jazz completes Orphan Medical buy
Jazz Pharmaceuticals says that it has completed the previously-announced $122.6 million acquisition of fellow US firm Orphan Medical (Marketletter April 25).
"The addition of Orphan Medical's products and experienced specialty salesforce establishes our commercial presence in our neurology and psychiatry franchises," said Robert Myers, executive vice president of Jazz Pharmaceuticals. "We are excited about continuing the clinical development of Xyrem (sodium oxybate), and we look forward to growing our commercial activities, both through acquiring additional products and by launching products from our internal product development pipeline," he added.
Zyrem is claimed to be the first treatment for cataplexy associated with narcolepsy and is currently under review with the US Food and Drug Administration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze